Participated · Equity · Aug 2026

Birdsview develops a platform that combines ground-penetrating radar, LiDAR and proprietary algorithms to turn sensor data into 3D models showing rebar position, thickness, cracks, voids and corrosion without drilling. The company launched its first concrete product in January 2025 and after beginning direct pre-sales in March 2026 customers in nine countries adopted the system within weeks. Birdsview started by building sensors to detect rot in wooden utility poles and expanded the approach to concrete; it was founded by Olav Skogen and Simen Husøy while students in Trondheim. The company operates from Bergen and Oslo and has 14 employees. Since launch it has scanned over 100 structures and counts clients such as Vinci, Bouygues Construction, EllisDon, Sweco, Asplan Viak and Rambøll. Customer examples include a Bergen contractor that used Birdsview to map rebar under a basement, saving about 200,000 NOK and two weeks of work.

Participated · Seed · Aug 2026

VISOID develops AI design visualization technology that allows architects and designers to create architectural renders more quickly and accessibly. In just over two years the platform has been used by architects in 120 countries to produce more than 5 million renders. Its user base ranges from independent practices to major firms such as OMA and Sweco. The company says it is scaling its team and accelerating product development to support international adoption. VISOID recently raised $2.5 million in seed funding to fund that expansion and product acceleration. Continued support from organizations including Startuplab, OBOS and Antler was also noted in reporting.

Participated · Seed · Jun 2026

Surfact develops sensor hardware and cloud-based software for real-time monitoring of temperature-sensitive shipments, tracking temperature, location and deviations across the transport chain. Its solution is currently deployed in 20 countries and has attracted customers such as Vitusapotek, Apotek 1, McDonald's, Posten Bring and BAMA. The company raised just over NOK 20 million in the recent financing to accelerate international growth, with a particular focus on the U.S. market and large global logistics and pharmaceutical clients. Surfact aims for NOK 50 million in annual recurring revenue by 2027 and over NOK 100 million by 2030. Leadership says the firm has built a small but effective team and is seeing strong global demand for its real-time cold-chain monitoring technology.

Participated · Seed · Nov 2025

Founded in October 2023 and based in Oslo, Noteless offers an AI scribe that leverages advanced speech recognition and natural language processing to create medical notes during patient consultations. The platform is designed to save clinicians up to two hours each day, easing administrative strain and allowing more time for patient care and personal well-being. Since launching its first product in June 2024, the company’s paying customer base has grown by more than 360 percent. Adoption is especially strong in the Nordics, with over one in four general practitioners in Norway and one in seven in Denmark using the tool. The product is also gaining traction among specialist doctors, physiotherapists, and psychologists. With fresh capital, Noteless plans to broaden its reach across Europe while continuing to enhance its AI technology and support high-quality patient care.

Participated · Equity · Sep 2025

Founded in 2020, Scindo has built a proprietary, data-rich platform that combines experimentally validated reaction datasets with advanced AI models to discover, design and optimise novel enzymes. These enzymes catalyse the conversion of challenging, renewable feedstocks directly into bio-active ingredients, offering a sustainable alternative to petroleum-derived chemicals. The company positions its technology as a full-stack solution that enables consistent, scalable production of natural ingredients across multiple high-value sectors such as food, flavourings, cosmetics and specialty chemicals. Industry traction is already evident through partnerships with leading specialty chemical manufacturers and pilot-scale initiatives aimed at bringing the first products to market. Recent hiring from top pharmaceutical firms and the University of Oxford has strengthened expertise in machine learning, enzyme engineering, process scaling and commercialisation. Proceeds from the latest funding will expand the enzyme discovery engine, scale wet-lab capabilities and grow the team. The company did not disclose revenue or user metrics, but investor interest highlights strong demand for bio-based solutions that deliver both performance and sustainability.